The founders of Noble Life Sciences, a Gaithersburg, Maryland-based preclinical research services company, have launched a new investment capital fund.
BlackRock BioCapital will focus on creating and funding early stage technology-oriented biomedical companies developing novel therapeutic and diagnostic products.
Leveraging the management and R&D infrastructure at Noble Life Sciences, the fund expects to make its first investment by the end of 2011.
Dr. Kenneth Carter, CEO of Noble Life Sciences, is also Managing Partner of BlackRock BioCapital.
FinSMEs
30/06/2011